SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Corbus to Present CRB-913 Study Data at Obesity Week 2026

Corbus Pharmaceuticals said late-breaking data from its CRB-913 Canyon-1 Phase 1B study will be presented as a poster at Obesity Week 2026.

CRBP

Related stories